Asset
COFIRASERSEN
IONIS PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03647228 | phase1 | completed | 2018-12-13 | 2020-10-13 | Ionis Pharmaceuticals, Inc. | A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis |
| NCT04441788 | phase2 | terminated | 2020-12-22 | 2021-04-27 | Ionis Pharmaceuticals, Inc. | A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) |
FDA applications (0)
This company has no applications containing this asset.